Wegovy AI visibility climbed in October: the share of Weight loss telehealth providers answers naming it rose from 34% to 51%, and it moved from 6th to 3rd place. Longer lists explain part of that. How much of the gain is real, and where did it come from?
Key Takeaways
- Wegovy was named in 51% of answers, up from 34%. Beyond longer lists, it gained 11.5 points.
- It climbed from 6th to 3rd place, and four of five assistants showed the gain.
- Safety and Trust questions moved most, each up 34.0 points. Claude and Perplexity moved most among assistants.
- Calibrate, Found and WeightWatchers moved the other way.
- Sesame, Fortune, Forbes and NIH pages rose in citations, but no source we found explains the gain.
What changed for Wegovy in AI answers?
Wegovy was named in 34% of the category's AI answers in September and 51% in October. That share counts the answers that name the brand. It is not market share or sales. The raw gain was 16.9 points.
The raw gain overstates the move. Answers named more brands in October: 4.23 names per answer before and 4.85 after. Longer lists lift every brand's share, so we remove that lift. Beyond it, Wegovy gained 11.5 points.
Its place in the category moved from 6th to 3rd, a climb of 3 places. Four of five assistants showed the gain. It also held week after week: the adjusted gain was 14.9 points for the week of October 12, 10.1 points for October 19 and 8.8 points for October 26. It narrowed, but it stayed positive every week.
Which assistants moved most?
The comparison runs on AI Overview, Claude, Copilot, Gemini and Perplexity. AI Mode and ChatGPT were not compared: fewer than two weekly runs in one of the months.
- Claude moved most. Its share for Wegovy went from 21% to 53%, an adjusted gain of 23.8 points.
- Perplexity followed, from 19% to 50%, or 18.4 points beyond longer lists.
- Gemini rose from 27% to 36%.
- AI Overview moved least beyond list length, at 4.0 points. It already named Wegovy often, going from 53% to 67%.
Copilot barely changed in raw terms, from 49% to 48%. The gain came mostly from the two assistants that started low.
Where did Wegovy move most, by topic and question?
The raw share changes below come from the topics of the questions we ask. Three topics stand out.
- Safety: 46% to 80%, up 34.0 points.
- Trust: 43% to 77%, up 34.0 points.
- Exploratory: 36% to 50%, up 14.0 points.
Expert recommendation moved only 4.0 points, and Price and value moved 2.0 points. Three questions carried the change:
- "Which online weight loss providers are safest when you never see a doctor in person?" went from 33% to 80%, up 47.0 points.
- "Which online weight loss providers are the most reputable?" went from 8% to 53%, up 45.0 points.
- "Which weight loss programs help you keep the weight off after you stop?" went from 9% to 40%, up 31.0 points.
The safety question shows how the assistants describe Wegovy. In September, it was a yardstick for what to look for.
FDA-Approved Drugs: Prioritize providers offering name-brand, FDA-approved medications (such as Wegovy or Zepbound) over unverified compounded peptides.
AI Overview, September 21, answering “Which online weight loss providers are safest when you never see a doctor in person?”
In October, Gemini kept that framing. Claude went further and placed Wegovy inside a named provider's treatment plan.
FDA-Approved Prescriptions & Transparent Sourcing: The safest programs prioritize branded, FDA-approved medications (such as Wegovy, Zepbound, Saxenda) and clearly disclose the safety and pharmacy source if compounded medications are utilized.
Gemini, October 5, answering “Which online weight loss providers are safest when you never see a doctor in person?”
Providers on Mochi Health are obesity specialists who provide personalized treatment plans, which may include weight loss medications like Wegovy or compounded semaglutide.
Claude, October 19, answering “Which online weight loss providers are safest when you never see a doctor in person?”
This is what the answers show. It is not proof of why the share rose.
Which brands lost ground as Wegovy rose?
Three brands moved the other way once longer lists are removed. Calibrate fell from 40% to 33% and from 5th to 7th place, losing 12.0 points. Found went from 48% to 47% and from 3rd to 6th place, losing 8.5 points.
WeightWatchers held 1st place at 72%. Even so, it lost 7.7 points beyond list length.
The same pattern shows in the questions where Wegovy moved most. Across 29 question-and-assistant cells, the brands named less were Calibrate, from 53% to 37%, and Found, from 50% to 46%. Sequence slipped from 17% to 13%.
Which sites did the assistants cite when naming Wegovy?
We look at answers that named Wegovy and cited a source: 58 in September and 110 in October. The figures below are the percent of those answers citing each site.
- Rose: sesamecare.com from 3% to 21%, fortune.com from 10% to 25%, forbes.com from 28% to 42% and nih.gov from 2% to 14%.
- Fell: joinfound.com from 28% to 6%, teleranked.com from 12% to 1%, youtube.com from 26% to 16% and fda.gov from 16% to 6%.
The page cited most was a Forbes guide to online weight loss medication, in 30 answers. A U.S. News ranking of weight loss medication providers appeared in 23. A Sesame online weight loss program page appeared in 18.
The fall of joinfound.com, whose name matches rival Found, fits the rival's slide in places. These are what the answers show, not causes. We found no story or cited page that explains the gain.
How does the benchmark page show the change?
The benchmark page shows a brand's share and place in each month from one run each. It can differ from the month's pooled numbers, and here it does. The page shows Wegovy at 45% and 3rd place, then 54% and 4th place. The pooled figures used in this article are 34% and 6th place, then 51% and 3rd place.
For the full picture, open the category report or explore the category. The October 2026 report covers every category.
How we measured this
We sent the same questions to the same assistants every week of both months: four weeks in October, from October 5 to October 26, and three weeks in September. The window holds 422 answers from 7 weekly runs, September 14 to October 26. We then adjust each change for longer lists. A paired test over 80 question-and-assistant pairs, with a false discovery rate correction, gives a q value of 0.02. A winner must gain ten points beyond longer lists, climb two places, gain on two assistants or more, and gain every week. Wegovy cleared each bar.
Wegovy's gain in October holds after adjusting for longer lists: 11.5 points beyond them, across four of five assistants and every week. Safety and trust questions carried it, while Calibrate and Found gave ground. The cited sites show where answers looked, and no source we found explains the gain. Will it last into the next report?
Frequently Asked Questions
How much did Wegovy's AI visibility rise?
Wegovy was named in 51% of the category's AI answers in October, up from 34% in September. That is a raw gain of 16.9 points. After removing the lift from longer lists, the gain is 11.5 points.
What does the adjusted change for Wegovy mean?
Answers named more brands per answer in October, rising from 4.23 to 4.85. Longer lists raise every brand's share. The adjusted change is what Wegovy gained beyond that.
Which assistants showed the biggest gain for Wegovy?
Claude moved most, from 21% to 53%. Perplexity came next, from 19% to 50%. AI Overview moved least beyond list length, at 4.0 points.
Which brands lost ground while Wegovy gained?
Calibrate, Found and WeightWatchers all moved the other way once longer lists are removed. Calibrate lost 12.0 points, Found lost 8.5 points and WeightWatchers lost 7.7 points. WeightWatchers still held 1st place.
What counts as a winner in the benchmark?
A winner gains at least ten points beyond longer lists and climbs at least two places. It must also gain on two assistants or more, and every week must go its way. Wegovy met each of those bars.
